



Clinical trial results: A 6-MONTH, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN ADOLESCENT PATIENTS WITH FIBROMYALGIA

Summary

EudraCT number	2010-020300-29
Trial protocol	CZ
Global end of trial date	01 June 2015

Results information

Result version number	v1 (current)
This version publication date	24 February 2016
First version publication date	24 February 2016

Trial information

Trial identification

Sponsor protocol code	A0081231
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01020526
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 East 42nd Street, New York, NY, United States, 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., +1 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., +1 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 September 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 June 2015
Global end of trial reached?	Yes
Global end of trial date	01 June 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety of pregabalin at doses of 75-450 mg/day (taken in twice daily [BID] doses) in participants who participated in the double-blind fibromyalgia study A0081180 and who wished to receive open-label pregabalin therapy.

Protection of trial subjects:

The study was conducted in accordance with the protocol, legal and regulatory requirements, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), Guidelines for Good Clinical Practice (GCP) (International Conference on Harmonization [ICH] 1996), and the Declaration of Helsinki (World Medical Association 1996 and 2008). In addition, the study was conducted in accordance with applicable local regulatory requirements and laws.

Background therapy:

This study has no background medication therapy.

Evidence for comparator: -

Actual start date of recruitment	01 September 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 40
Country: Number of subjects enrolled	India: 20
Country: Number of subjects enrolled	Czech Republic: 3
Worldwide total number of subjects	63
EEA total number of subjects	3

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	63
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 63 participants were screened and enrolled at 19 study centers in this open-label extension study to the parent double-blind randomized fibromyalgia study A0081180.

Pre-assignment

Screening details:

Participants initiated dosing at 75 mg/day and their dose was optimized over a 3 week period, based on tolerability and response, to a dose of 75 mg/day, 150 mg/day, 300 mg/day or 450 mg/day.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	Pregabalin
-----------	------------

Arm description:

Participants initiated dosing at 75 mg/day, and their dose was optimized over a 3 week period based on tolerability and response to a dose of 75 mg/day, 150 mg/day, 300 mg/day or 450 mg/day. These doses were administered during the subsequent flexible dosing phase for a period of 21 weeks. Pregabalin was administered orally as capsules.

Arm type	Experimental
Investigational medicinal product name	Lyrica
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

75 mg/day to 450 mg/day

Number of subjects in period 1	Pregabalin
Started	63
Completed	49
Not completed	14
Consent withdrawn by subject	5
Adverse event, non-fatal	2
Other reasons	3
Lost to follow-up	1
Insufficient clinical response	3

Baseline characteristics

Reporting groups

Reporting group title	Pregabalin
-----------------------	------------

Reporting group description:

Participants initiated dosing at 75 mg/day, and their dose was optimized over a 3 week period based on tolerability and response to a dose of 75 mg/day, 150 mg/day, 300 mg/day or 450 mg/day. These doses were administered during the subsequent flexible dosing phase for a period of 21 weeks. Pregabalin was administered orally as capsules.

Reporting group values	Pregabalin	Total	
Number of subjects	63	63	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	63	63	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age Continuous Male			
Units: years			
arithmetic mean	14.8		
standard deviation	± 1.4	-	
Gender, Male/Female			
Units: Participants			
Female	53	53	
Male	10	10	

End points

End points reporting groups

Reporting group title	Pregabalin
Reporting group description:	
Participants initiated dosing at 75 mg/day, and their dose was optimized over a 3 week period based on tolerability and response to a dose of 75 mg/day, 150 mg/day, 300 mg/day or 450 mg/day. These doses were administered during the subsequent flexible dosing phase for a period of 21 weeks. Pregabalin was administered orally as capsules.	

Primary: Change from baseline in pain numeric rating scale by week

End point title	Change from baseline in pain numeric rating scale by week ^[1]
End point description:	
The weekly pain numeric rating scale (Weekly Pain NRS) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain. Participants chose the number that best described the pain during the last week.	
End point type	Primary
End point timeframe:	
Baseline, Weeks 3, 8, 16, 24 and Last Visit.	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this primary endpoint

End point values	Pregabalin			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Units on a Scale				
arithmetic mean (standard deviation)				
Baseline (N=63)	6.7 (± 1.68)			
Week 3 (N=61)	-2.1 (± 2.51)			
Week 8 (N=55)	-1.8 (± 2.95)			
Week 16 (N=51)	-2.1 (± 2.6)			
Week 24 (N=55)	-2.1 (± 2.56)			
Last Visit (N=63)	-2.1 (± 2.47)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All adverse events were recorded from the time the participants had taken at least 1 dose of study drug through the last subject visit.

Adverse event reporting additional description:

For summary purposes, adverse event investigator terms were converted to preferred terms using a standard system of classification (COSTART or MedDRA). Adverse events tabulations included summaries by body system or system organ class, by overall decreasing frequency and by maximum intensity.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	18.0

Reporting groups

Reporting group title	Pregabalin
-----------------------	------------

Reporting group description:

Participants initiated dosing at 75 mg/day and their dose was optimized over a 3 week period, based on tolerability and response, to a dose of 75 mg/day, 150 mg/day, 300 mg/day or 450 mg/day.

Serious adverse events	Pregabalin		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 63 (4.76%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Nervous system disorders			
Migraine			
subjects affected / exposed	1 / 63 (1.59%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Joint instability			
subjects affected / exposed	1 / 63 (1.59%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 63 (1.59%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Pregabalin		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 63 (50.79%)		
Nervous system disorders			
Dizziness			
subjects affected / exposed	14 / 63 (22.22%)		
occurrences (all)	16		
Headache			
subjects affected / exposed	6 / 63 (9.52%)		
occurrences (all)	10		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	8 / 63 (12.70%)		
occurrences (all)	11		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	5 / 63 (7.94%)		
occurrences (all)	5		
Abdominal pain upper			
subjects affected / exposed	5 / 63 (7.94%)		
occurrences (all)	6		
Nausea			
subjects affected / exposed	5 / 63 (7.94%)		
occurrences (all)	7		
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	3 / 63 (4.76%)		
occurrences (all)	4		
Respiratory, thoracic and mediastinal disorders			

Nasal congestion subjects affected / exposed occurrences (all)	4 / 63 (6.35%) 4		
Infections and infestations			
Ear infection subjects affected / exposed occurrences (all)	4 / 63 (6.35%) 4		
Upper respiratory tract infection subjects affected / exposed occurrences (all)	4 / 63 (6.35%) 6		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
31 December 2012	Updated Pfizer protocol template wording was implemented. Information regarding the importance of parent/guardian/caregiver involvement in overseeing subject participation, especially dosing, was added.
14 March 2014	The Columbia Suicide Severity Rating Scale (C-SSRS) was added as a required study assessment.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported